Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N A Vick

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
British Journal of Cancer|August 17, 2000
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseW K Yung, R E Albright, J Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial resultsD D Bigner, M T Brown, A H Friedman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1996
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial resultsM T Brown, R E Coleman, A H Friedman, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
British Journal of Cancer|August 17, 2000
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseW K Yung, R E Albright, J Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial resultsD D Bigner, M T Brown, A H Friedman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1996
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial resultsM T Brown, R E Coleman, A H Friedman, et al.
Pageof 7